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Genome-wide analysis of a multi-incident family with autosomal-dominant parkinsonism has implicated a locus on chromosomal
region 3q26-q28. Linkage and disease segregation is explained by a missense mutation c.3614G>A (p.Arg1205His) in eukaryotic
translation initiation factor 4-gamma (EIF4G1). Subsequent sequence and genotype analysis identified EIF4G1 c.1505C>T
(p.Ala502Val), c.2056G>T (p.Gly686Cys), c.3490A>C (p.Ser1164Arg), c.3589C>T (p.Arg1197Trp) and c.3614G>A (p.Arg1205His)
substitutions in affected subjects with familial parkinsonism and idiopathic Lewy body disease but not in control subjects. Despite
different countries of origin, persons with EIF4G1 c.1505C>T (p.Ala502Val) or c.3614G>A (p.Arg1205His) mutations appear to share
haplotypes consistent with ancestral founders. eIF4G1 p.Ala502Val and p.Arg1205His disrupt eIF4E or eIF3e binding, although the
wild-type protein does not, and render mutant cells more vulnerable to reactive oxidative species. EIF4G1 mutations implicate
mRNA translation initiation in familial parkinsonism and highlight a convergent pathway for monogenic, toxin and perhaps virally-
induced Parkinson disease.Introduction
Parkinson disease (PD [MIM 168600]) is characterized clin-
ically by asymmetric resting tremor, bradykinesia, muscle
rigidity, and postural instability.1 Dopaminergic loss and
Lewy bodies in surviving neurons of the substantia nigra
support a pathologic diagnosis.2 Although considered a
sporadic illness, 10%–30% of individuals with PD report
a first-degree relative with parkinsonism.3 Linkage and se-
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a-synuclein (SNCA [MIM 163890]), leucine-rich repeat
kinase 2 (LRRK2 [MIM 609007]), vesicular protein sorting
35 (VPS35 (MIM 601501]), Parkin (PARK2 [MIM
602544]), PTEN induced putative kinase 1 (PINK1 [MIM
608309]), DJ-1 (PARK7 [MIM 602533]) and ATP13A2
(PARK9 [MIM 610515]).4,5 Although familial parkinsonism
attributed to mutant genes is uncommon, the molecular
etiology discovered might be generalizable to idiopathic
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Figure 1. Pedigrees with EIF4G1 Mutations and Parkinsonism
Individual pedigrees are numbered and their country of origin is indicated. Only pedigrees with an (A) EIF4G1 c.3614G>A
(p.Arg1205His), (B) c.1505C>T (p.Ala502Val), (C) c.2056G>T (p.Gly686Cys), (D) c.2056G>T (p.Gly686Cys) and c.3589C>T
(p.Arg1197Trp) and (E) c.3490A>C (p.Ser1164Arg) mutations are illustrated. Filled symbols indicate affected individuals with parkin-
sonism; the age of symptom onset is shown in parentheses. Quarter-filled symbols indicate individuals with dementia. To protect confi-
dentiality, the pedigrees do not show some individuals and siblings and/or gender is sometimes disguised with a diamond. All samples
genotyped are indicted as heterozygous mutations (M) or as wild-type (wt). The asterisk (*) indicate that this individual did not fulfill the
criteria for PD, but presented resting tremor and akinesia.Lewy bodies and neuritic pathology,6 whereas mutations
in Parkin and PINK1 have emphasized the role of stress-
induced mitochondrial dysfunction in PD.7
We have performed genome-wide linkage analysis of a
multi-incident northern French family (P30; Figure 1A)The Americanwith autosomal-dominant late-onset parkinsonism for
which known genetic causes of parkinsonism were ex-
cluded (unpublished data).8 Linkage analysis identified
two regions with suggestive two-point LOD scores > 2
(q ¼ 0), a 31 cM interval between D3S1763 and D3S1580,Journal of Human Genetics 89, 398–406, September 9, 2011 399
and a 15 cM interval between D5S2055 and D5S393. After
saturation of both loci with short tandem repeat (STR)
markers, significant linkage was obtained only for chromo-
somal region 3q26-q28. Genomic analysis subsequently
led to the identification of eukaryotic translation initiation
factor 4-gamma 1 (EIF4G1) mutations (protein eIF4G1
[MIM 600495]) in affected subjects with familial parkin-
sonism and idiopathic Lewy body disease. eIF4G1 is a com-
ponent of the translation initiation complex, eIF4F.9,10 We
demonstrate that the two most frequent mutations impair
complex formation, consistent with a dominant-negative
loss of function, and are associated with mitochondrial
dysfunction when cells are stressed.Subjects and Methods
Subjects Ascertainment
The institutional review boards of all participating institutions
approved the protocol (institutional review boards France CPP
94/07), and informed consent was obtained from all affected
and control subjects. Participating individuals were examined by
neurologists specializing in movement disorders. A full history,
including a family history and a neurological examination, was
completed for each patient. A clinical diagnosis of PD was deter-
mined by the presence of at least two of three cardinal signs
(resting tremor, bradykinesia, and rigidity), improvement through
adequate dopaminergic therapy (when tried), and the absence of
atypical features or other causes of parkinsonism. Clinical criteria
for probable and possible PD were consistent with former classifi-
cations.1,2 Familial history is defined herein as one or more
affected relatives within two degrees of relationship.Linkage Analysis
Peripheral blood samples were collected and genomic DNA was
extracted with standard techniques. Tri- and tetra-nucleotide
repeat genome-wide genotyping was completed by the mamma-
lian genotyping service of Marshfield in family P30, for 403
markers at approximately 10 cM resolution. Linkage analysis
employed MLINK with a dominant model for two-point LOD
scores and SIMWALK2 for nonparametric statistics and haplotype
analysis.11,12 The frequency of the deleterious allele was set at
0.0001; marker-allele frequencies were from CEPH or determined
empirically. The map positions for each marker were taken from
Marshfield and Rutgers combined linkage physical map.13 For
tightly linked loci with no observed recombinants the intermarker
genetic distances were assigned as 0.01 cM.Sequencing Analysis and Mutation Screening
Gene sequencing of all coding exons in the 3q26-q28 interval was
performed for the three affected members of family P30 (individ-
uals with symptom onset of 61, 62, and 56 years [Figure 1A,
III-2, III-3, III-5]) with an ABI 3730 sequencer with SeqScape v2.5
analysis software (Applied Biosystems). Electrophoregrams were
compared with CEPH 1331-01 and -02 control subjects obtained
from Genethon and the human reference sequence from the
UCSC database. Primers designed for amplification of all exons
including exon-intron junctions of EIF4G1 are provided in Table
S1, available online. Mutations segregating with the disease were
further assessed in the other P30 members (n ¼ 23), in control400 The American Journal of Human Genetics 89, 398–406, Septembsubjects of the northern French (n ¼ 146), and in other subjects
of European descent (n ¼ 370). RefSeq accessions NM_198241.2
and NP_937884.1 were used to number all variants within the
EIF4G1 gene and protein.
Further sequencing of all EIF4G1 coding exons was then per-
formed to identify other mutations in additional subjects affected
with autosomal-dominant parkinsonism (n ¼ 95) or neuropatho-
logically confirmed Lewy body disease (n ¼ 130) and ethnically
matched controls (n ¼ 185).
In order to test whether EIF4G1 missense mutations might be
found in idiopathic PD, we genotyped a large case-control series
consisting of 4430 affected and 3671 control subjects of European
descent (North America: 2092 PD [130 Lewy body disease], 1666
controls [provided by Z.K.W., R.J.U., D.W.D., R.F., D.M.M.,
PROGENI]; Norway: 775 PD, 614 controls [J.O.A.]; France: 574
PD, 469 controls [M.-C.C.-H., A.D.]; Ireland: 400 PD, 460 controls
[D.G., T.L., M.H.]; Poland: 397 PD, 366 controls [A.K.-W., G.O.];
Italy: 192 PD, 96 controls [A.R.B., E.M.V.]) and 278 affected
and 379 control subjects of Arab-Berber ethnicity from Tunisia
[F.H., R.A.G.]. Genotyping was performed with the Sequenom
MassArray iPLEX platform (San Diego, CA). All primer sequences
are available on Table S1. All mutations discovered were confirmed
by direct sequencing.Chromosome 3 Haplotype Analysis
STRandSNPmarkerswerechosentospantheEIF4G1 locus, including
D3S3037, Chr3_179.425, D3S3730, D3S3699, Chr3_182.108,
D3S2312, D3S2314, Chr3_184.176, Chr3_184.543, Chr3_184.806,
D3S1571, Chr3_185.212, Chr3_185.320, Chr3_185.398,
Chr3_185.425, Chr3_185.464, D3S3609, Chr3_185.526, D3S3578,
Chr3_185.619, Chr3_185.633, Chr3_185.653, Chr3_185.692,
D3S3583, Chr3_185.822, Chr3_185.860, Chr3_185.870, D3S3592,
Chr3_186.199, D3S1530, D3S1262, D3S2436, D3S3686, D3S3651,
andD3S1580 (Table S2). Eighteenof these STRmarkers arenovel (pre-
fixed with Chr3_ as ‘‘D segment’’ numbers are no longer available)
and were designed by searching for repeat polymorphisms in 6.77
Mb of genomic sequence spanning the locus. One primer of each
pair was labeled with a fluorescent tag; amplified sequences are
available on Table S1. PCR reactions were performed under standard
conditions and products were run on an ABI 3730 genetic analyzer.
Results were analyzed with GeneMapper 4.0 software (Applied
Biosystems). Five SNPs located in EIF4G1, rs4912537, rs2178403,
rs2293605, rs1879244 and rs2230571, were included. Marker-allele
frequencies for the European population were obtained from the
CEPHgenotypedatabase, theHumanHapMapdatabase,orestimated
by genotyping100unrelatedhealthy subjects fromNorthAmerica of
European descent. NCBI build 36.1 is referenced throughout.Testing for EIF4G1 Copy-Number Variation
To determine whole-gene copy number, primer pairs, and probes
were designed against exon 10, 18, and 24 of EIF4G1. An endoge-
nous control assay was designed against exon 5 of the presenilin
2 gene. All primers and probes were purchased from Applied
Biosystems and sequences are available on Table S1. Quantitative
PCR was carried out with TaqMan expression chemistry protocol;
25 ng genomic DNA was amplified with 0.25 ml primer probe and
2.5 ml TaqMan 2XUniversal PCRMasterMix (Applied Biosystems).
The thermal cycle conditions were performed at 50C for 2 min
and at 95C for 10 min, followed by 40 cycles at 95C for 15 s
for denaturation and at 60C for 1 min for annealing and exten-
sion. All assays were performed in triplicate on the ABI 7900HTer 9, 2011
Fast Real-Time PCR System and analyzed with ABI SDS 2.2.2
Software (Applied Biosystems).EIF4G1 Cloning and Coimmunoprecipitation Studies
of Protein-Complex Binding Partners
Full-length EIF4G1 wild-type (WT) and a dominant negative
mutant were amplified from plasmids as previously described14
and subcloned into pcDNA6.2-V5 and pcDNA6.2/C-EmGFP-Dest
expression vectors. The eIF4G1 p.Ala502Val and p.Arg1205His
mutations were subsequently introduced with site-specific muta-
genesis (primers available in Table S1). HEK293T cells, maintained
in Opti-mem 1þGlutaMAX1 with 10% of fetal calf serum and
penicillin/streptomycin (all GIBCO) at 37C and 5% CO2, were
transfected with cDNA encoding the respective WT or mutant
eIF4G1-V5 proteins with Lipofectamine 2000 according to the
manufacturer’s instructions (Invitrogen). Cells were harvested
48 hr after transfection and lysed in 50 mM Tris/HCL, 150 mM
NaCl, and 0.1% Triton X-100. To avoid unspecific binding during
immunoprecipitation, we precleared crude lysates by rotating
them at 4C for 1 hr with Protein A/G ultralink resin (Thermo
Scientific) followed by centrifugation at 13,000 3 g for 10 min.
After performing a BCA Protein assay (Pierce), equal amounts of
supernatant were combined with protein G Dyna beads (Invitro-
gen) preconjugated with monoclonal mouse anti-V5 antibodies
(Invitrogen) and rotated on a spinning wheel for 4 hr at 4C.
The resulting immunocomplex was stringently washed with
intraperitoneal (IP) buffer/PBS and eluted in SDS-Sample buffer
(Invitrogen). Immunoprecipitated and coprecipitated proteins
were analyzed with SDS PAGE/immunoblot technologies. For
protein detection, monoclonal anti-V5 (Invitrogen) and poly-
clonal rabbit eIF4E, eIF3e, and eIF4A (Abcam) were applied. ImageJ
was used to quantify the relative amounts of copurified interactors
eIF4A1, eIF4E, and eIF3e, taking into account the amounts in the
full lysates and the amount of immunoprecipitated eIF4G1
proteins. One-way ANOVA was applied for statistical analysis.Assessment of Mitochondrial Function by Flow
Cytometry
HEK293T cells were transfected with plasmids encoding
GFP-tagged eIF4G1 proteins (WT, p.Ala502Val, and p.Arg1205His)
and subsequently subjected to viability studies with fluorescence
activated cell sorting (FACS) analysis. Incorporation of the mito-
chondrial-permeable dye tetramethyl rhodamine ethyl ester
(TMRE; Invitrogen) has been shown to reflect mitochondrial
activity and was used as an indicator for cellular viability. Cells,
maintained at 37C in Opti-mem 1þGlutaMAX1 with 10% fetal
calf serum medium (both GIBCO), were seeded at a density of
150,000 cells/6-well and transfected 24 hr prior to FACS analysis.
Duplicates of each condition were treated with either 0 or
0.5mMH2O2 for 6 hr. Labeling with 100 nMTMREwas performed
by directly adding TMRE from a DMSO stock solution (0.2 mM) to
the growth medium and incubating for 30 min at 37C. After two
washing steps with warm PBS containing 1% FBS, cells were trypsi-
nized, resuspended, and immediately subjected to FACS analysis.
We established specific settings for the separation into transfected
(GFP positive) and untransfected (GFP negative) as well as viable
(TMRE positive) and TMRE negative cells by using appropriate
controls including (1) untransfected, no TMRE; (2) transfected,
no TMRE; (3) untransfected, TMRE stained; and (4) transfected,
TMRE stained samples. For each sample, 100,000 events were
acquired and subsequently analyzed. After removal of backgroundThe Americancounts and the exclusion of untransfected (GFP negative) cells,
average TMRE loading values were based on at least 25,000
cells. The number of TMRE positive cells were calculated as the
percentage of the total number of GFP positive cells in the respec-
tive sample.Results
Genetic and Physical Mapping
Genome-wide analysis of the P30 pedigree led us to
identify two regions with suggestive two-point LOD
scores > 2 (q ¼ 0), a 31 cM interval between D3S1763
and D3S1580, and a 15 cM interval between D5S2055
and D5S393. The two loci on chromosomes 3 and 5 were
saturated with STRs at <2.0 cM resolution to maximize
genetic information, and genotype segregation with
disease was reanalyzed with additional DNA samples
from family P30. Significant linkage was obtained only
for chromosomal region 3q26-q28 (mLOD ¼ 3.01) with
a haplotype shared by all affected relatives.
Identification of an EIF4G1 Mutation in Family P30
In silico analysis revealed that the critical interval contained
159 genes (1432 exons). We sequenced each of these along
with their donor and acceptor splice sites by using genomic
DNA samples from three affected first cousins of P30
(Figure 1A; III-2, III-3, III-5). We found 236 known SNPs
and 33 novel variants with only five that were present
in all three affected family members sequenced; three
intronic variants were located more than 20 bases from
exon-intron boundaries. Of those novel variants, only
EIF4G1 mutation c.3614G>A (p.Arg1205His) was found
to segregate with disease in all ten blood-related, affected
family members (family P30 two-point LOD¼ 3.55, q¼ 0).
The mutation was absent in 146 unrelated control subjects
from the same ethnical and geographical origin and in
370unrelatedNorthAmericancontrol subjects of European
descent. Because chromosome 3q26-q28 is a fragile site in
cancer and genomic multiplications are associated with
malignancy,10 probes in EIF4G1 were used to grossly assess
copy number variants but none were found (n ¼ 225
affected subjects).
eIF4G1 c.3614G>A is located in exon 24 of a 33 exon
gene. It predicts the substitution of a conserved arginine
to histidine at residue 1205 (p.Arg1205His) of the protein.
A cross-species alignment of the eIF4G1 demonstrated the
p.Arg1205His is highly conserved across species (Figure S1).
In silico analysis predicts the mutation might be damaging
to protein function (Polyphen-2 PSIC score ¼ 0.99).
Screening of EIF4G1 c.3614G>A (p.Arg1205His)
in Individuals with PD
To further investigate the pathogenicity of the EIF4G1
c.3614G>A (p.Arg1205His), we genotyped 4050 control
subjects and 4708 individuals with idiopathic PD. We
identified nine affected heterozygotes from seven families
originating from the US (385-1493, 2498), Canada (2499),Journal of Human Genetics 89, 398–406, September 9, 2011 401
Figure 2. Disease-Segregating EIF4G1 c.3614G>A Haplotypes among Families
(A) Comparison of haplotype data among all families with EIF4G1mutations shows alleles between rs4912537 and D3S3578 are shared
(Table S2). The maximum shared interval is 99,330 bp (MAX; chr3:185,519,706–185,619,035; gray and blue bars) and contains six gene
transcripts, EIF4G1, FAM131A, CLCN2, POLR2H, THPO, and CHRD. The minimal shared interval is 45,676 bp (MIN; chr3:185,521,663-
185,567,338; gray) and harbors four genes (EIF4G1, FAM131A, CLCN2, and POLR2H). EIF4G1 c.3614G>A (p.Arg1205His) is the only
novel coding variant that segregates with disease.
(B) The CEU haplotype map suggests negligible linkage disequilibrium across the rs4912537–D3S3578 region.Ireland (32150- 50), Italy (GE0925 and GE1843), and
Tunisia (Tun83) (Figure 1A). A family history of parkin-
sonism was not evident in the Irish (32150-50), one Italian
(GE0925), or the Tunisian (Tun83) subjects. In contrast,
eIF4G1 p.Arg1205His was absent in control subjects.
To determine whether the EIF4G1 c.3614G>A
(p.Arg1205His) mutation segregates with disease in these402 The American Journal of Human Genetics 89, 398–406, Septembseven cases, we genotyped 42 STRs distributed across the
3q26-q28 locus flanking EIF4G1 c.3614G>A (Figure 2A;
Table S2A). Haplotype analysis shows that each affected
member of all seven families shares a minimal interval of
45,676bp (chr3:185,521,663-185,567,338) in common
with family P30. With the exception of EIF4G1
c.3614G>A (p.Arg1205His) no other novel coding varianter 9, 2011
segregates with the disease in this shared haplotype, in
which linkage disequilibrium between neighboring
variants is marginal (Figure 2B). The results suggest the
deleterious EIF4G1 c.3614G>A (p.Arg1205His) mutation
originates from an ancestral founder and segregates with
disease in seemingly unrelated families.
Screening for Novel EIF4G1 Variants in Other Families
To further evaluate the EIF4G1 mutations in PD, the 31
coding exons were sequenced in 95 randomly selected
affectedprobandswithautosomal-dominantparkinsonism,
130 pathologically-defined cases with Lewy body disease,
and 185 ethnically matched controls. Sequence analysis
identified eight novel coding variants in affected subjects
(4 missense, 4 silent), three novel changes in controls (two
missense, one silent), and three novel coding variants in
affected and control subjects (Table S3). The four missense
mutations not observed in controls were c.1505C>T
(p.Ala502Val), c.2056G>T (p.Gly686Cys), c.3490A>C
(p.Ser1164Arg), and c.3589C>T (p.Arg1197Trp) (Table S3).
They were detected in two affected probands with parkin-
sonism (US 623, US 385-1391) and two autopsied cases
with Lewy body disease (US 331-5, US 331-95) (Figure 1B).
These four variants were subsequently genotyped in a
case-control series consisting of 4483 individuals with idio-
pathic PD and 3865 age, gender, and ethnically matched
control subjects. Screening identified only affected hetero-
zygotes p.Ala502Val (US 385-284 and Poland 1736-155)
and p.Gly686Cys (2 with PD in the family French P141),
whereas the p.Ser1164Arg and p.Arg1197Trp mutations
were not observed again in affected or control subjects.
Consistent with eIF4G1 p.Arg1205His, the p.Gly686Cys,
p.Ser1164Arg, and p.Arg1197Trp mutations are also evolu-
tionarily conserved in mammals (Figure S1). Similarly,
eIF4G1 p.Ala502Val is conserved in most mammals with
the exception of the rabbit that has a valine at this posi-
tion. Limited cross-species conservation typically argues
against pathogenicity, but the first alpha-synuclein
p.Ala53Thr mutation linked to PD is a notable prece-
dent.15 Assessment of segregation with disease was not
possible for p.Ala502Val, p.Gly686Cys, p.Ser1164Arg,
and p.Arg1197Trp mutations, and as a consequence
genetic evidence for pathogenicity is limited. STR marker
analysis of chromosomal region 3q26-q28 in all heterozy-
gotes with p.Ala502Val suggested an ancestral founder,
although the phase was only available for one pedigree
(Table S2A).
Clinical Findings and Neuropathological Analyses
Within family P30, the clinical phenotype among EIF4G1
c.3614G>A (p.Arg1205His) heterozygotes is consistent
with late-onset PD, with a mean onset of 64 5 10.3 stan-
dard deviation (SD) years (n ¼ 10), but spans a broad range
(50–80 years) (Figure 1A). Symptoms start insidiously with
asymmetric resting tremor or akinetic rigidity and become
progressively mixed. The parkinsonism has a relatively
long, mild course, and cognition seems preserved. Patients’The Americansymptoms respond well to L-DOPA, but many remain
untreated or use only dopamine agonists. In clinically
symptomatic individuals’ dopaminergic imaging with
I-123 Ioflupan, DaTSCAN is abnormal and asymmetric.
The clinical phenotype among unrelated subjects with
a heterozygous EIF4G1 c.3614G>A (p.Arg1205His) muta-
tion was comparable to family P30 with a mean symptom
onset of 59 5 13.0 SD years (n ¼ 9), range 32–77 years
(Figure 1A). Overall, affected subjects with an EIF4G1
c.1505C>T (p.Ala502Val) mutation have a mean age of
symptom onset of 52 5 8.1 SD years (range 41–58 years,
n ¼ 4) (Figure 1B).
The ages at onset of subjects who have PD with other
EIF4G1 substitutions (c.2056G>T [p.Gly686Cys] and
c.3490A>C [p.Ser1164Arg]) were 55, 62, and 64, respec-
tively, in the France P141 and US 385-1391 families.
EIF4G1 mutations were also observed in two autopsy-
confirmed cases with Lewy body disease: an EIF4G1
c.1505C>T (p.Ala502Val) mutation in family US 331-5
and the double EIF4G1 mutant c.2056G>T (p.Gly686Cys)
and c.3589C>T (p.Arg1197Trp) in family US 331-95
(Figures 1B and 1D). The Lewy body pathology in these
cases is presented in Figure S2.
Functional Analyses of eIF4G1 p.Arg1205His
and p.Ala502Val Substitutions
eIF4G1 p.Arg1205His is just distal to the putative eIF3e
binding domain (amino acids 1015–1118; Figure S3), a
key partner of the translation initiation complex that
recruits the 40 S ribosomal subunit.16–18 Thus, we evalu-
ated WT and mutant eIF4G1 binding to eIF3e. Plasmids
containing eIF4G1 WT or eIF4G1 p.Arg1205His or
eIF4G1 LacZ were transfected into HEK293 cells. Coimmu-
noprecipitation studies of protein lysates from mutant
eIF4G1-transfected cells show that p.Arg1205His perturbs
eIF3e binding, but the WT protein does not (Figure 3).
eIF4G1 p.Ala502Val is the most frequent substitution
encountered in other familial cases, although genetic evi-
dence for segregation with disease and thus pathogenicity
is limited. Its physical location predicts that the substitu-
tion might perturb eIF4E binding (amino acids 612-618).
Coimmunoprecipitation studies of protein lysates from
mutant eIF4G1 transfected cells show p.Ala502Val per-
turbs eIF4E binding compared to WT protein (Figure 3).
Both p.Ala502Val and p.Arg1205His are located within or
proximal to the eIF4A-interacting domains (amino acids
761-988 and 1240-1450) but do not appear to affect its
binding, although a nonsignificant trend toward increased
binding was observed for p.Ala502Val.
When TMRE, a marker for mitochondrial membrane
polarization, was applied to either WT or mutant
(p.Ala502Val; p.Arg1205His) eIF4G1 transfected cells, no
differences could be detected under basal conditions.10
However, with hydroperoxide treatment, a profound loss
in mitochondrial membrane potential was observed for
both mutations but not for cells overexpressing WT
protein (Figure 4). Complementary results were obtainedJournal of Human Genetics 89, 398–406, September 9, 2011 403
Figure 3. Coimmunoprecipitation Studies of eIF4G1
p.Ala502Val and p.Arg1205His with eIF4A and eIF3e
Coimmunoprecipitation (CO-IP) of endogenous eIF4A, eIF4E, and
eIF3e with transfected full-length eIF4G1-V5 (WT, a dominant
negativemutant,13 or the p.Ala502Val and p.Arg1205Hismutants)
in HEK293T cells.
(A) The p.Ala502Val mutant perturbs the interaction with eIF4E
but not eIF4A (IP-V5). The inputs on the upper right panel repre-
sent the amounts of transfected eIF4G1-V5 (WTandmutants) and
the endogenous proteins (eIF4A1 or eIF4E) introduced in the
immunoprecipitation assay.
(B) Coimmunoprecipitation of eIF3e with eIF4G1-V5 (IP left;
inputs right). In the presence of the p.Arg1205His mutation signif-
icantly reduced amounts of eIF3e protein are coprecipitated
with eIF4G1-V5. Experiments were performed on three separate
occasions as depicted in the graphs. Representative immunoblots
are shown.with patient-derived lymphoblastoid cell lines (data not
shown). When starvation was used as an alternate stressor,
the induction of autophagy was comparable in WT and
mutant (p.Ala502Val; p.Arg1205His) overexpressing cells.404 The American Journal of Human Genetics 89, 398–406, SeptembThe lack of response might reflect the presence of endoge-
nous eIF4G1 (Figure S4).9Discussion
eIF4G1 is the core scaffold of a multisubunit translation
initiation complex that regulates the translation initiation
of mRNAs encoding mitochondrial, cell survival and
growth genes in response to different stresses.9,10 The path-
ogenicity of EIF4G1 mutations is supported by (1) the
segregation of eIF4G1 p.Arg1205His with disease in
a family with multi-incident autosomal-dominant, par-
kinsonism; (2) the absence of eIF4G1 p.Ala502Val and
p.Arg1205His in control subjects (n ¼ 4050), although
observed in several multi-incident families with auto-
somal-dominant late-onset PD; (3) an eIF4G1p.Arg1205His
haplotype suggestive of one ancestral founder, and de-
limiting the candidate gene interval; (4) the sequence
conservation of eIF4G1p.Ala502Val and p.Arg1205His sub-
stitutions suggesting these mutations might be function-
ally deleterious; and (5) impaired binding of eIF4G1
p.Ala502Val and p.Arg1205His to eIF4E or eIF3e, interac-
tions that are normally required for translation initia-
tion.17,18 Both p.Ala502Val and p.Arg1205His directly
impair formation of the larger eIF4 complex and support
the genetic argument for a dominant-negative loss-of-
function compatiblewith an age-dependent neurodegener-
ative disorder; (6) the loss of mitochondrial membrane
potential and viability in transfected cells subjected to
oxidative stress. The functional data presented are cursory
and further analyses of mitochondrial biogenesis, autoph-
agy, and transcription and translation, in additionalmodels
is warranted. A caveat of linkage within a multi-incident
family is that there remains a remote possibility of a miss-
ing segregating variant, most likely within the disease-
segregating haplotype. Although rare, additional EIF4G1
mutations in other families will be important to discover.
EIF4G1 mutations directly implicate mRNA translation
initiation in parkinsonism and might help unify other
monogenic forms, toxin, and perhaps virally-induced
disease within a convergent pathway.19,20 Availability of
eIF4E is generally the rate-limiting step of translation initi-
ation and is largely determined by phosphorylation of
eIF4E-binding proteins (4E-BP) through the mammalian
target of the rapamycin (mTOR) pathway.9,21 Constitutive
activity of mTOR signaling normally leads to phosphoryla-
tion of 4E-BPs; this dislodges eIF4E and enables assembly
of the eIF4F complex to promote cap-dependent transla-
tion (Figure S3).18 Notably, 4E-BP is a substrate of human
Lrrk2 and the Drosophila ortholog (Lrrk).22 Lrrk2 patho-
genic mutations cause hyperphosphorylation of 4E-BP
leading to reduced oxidative stress resistance and dopami-
nergic neurodegeneration. Conversely, inhibition of
mTOR signaling during development or overexpression
of 4E-BP in Drosophila mutants with PINK1 or Parkin loss-
of-function suppresses the flies’ pathologic phenotypes.23er 9, 2011
Figure 4. Fluorescence-Activated Cell-Sorting Analysis of
Mutant and Control Cell Lines HEK293T Cells Transiently Overex-
pressing WT or Mutant EIF4G1 (p.Ala502Val, p.Arg1205His)
eIF4G1-GFP proteins were subjected to FACS analysis, with TMRE
labeling applied as a marker of mitochondrial polarization.
Untreated eIF4G1-GFP-positive cells are comparable in terms of
TMRE loading. In contrast, with hydrogen peroxide treatment
p.Ala502Val- and p.Arg1205His eIF4G1-GFP-positive cells show
a 10% decrease in cell survival compared to WT cells. For each
sample, 100,000 events were acquired and subsequently analyzed.
After the removal of background counts and the exclusion of un-
transfected (GFP negative) cells, average TMRE loading values were
based on at least 25,000 cells. The number of TMRE-positive cells
was calculated as a percentage of the total number of GFP-positive
cells in the respective sample. Experiments with two duplicates
per condition were performed on three separate occasions.The variability in clinical and pathologic presentation
of affected members of EIF4G1 families is similar to genet-
ically-defined parkinsonism but most consistent with
idiopathic, late-onset Lewy body PD. Although EIF4G1
mutations represent a molecular mechanism for PD,
genetic defects in translation have been implicated in
many neurological diseases.24 Most are private mutations
in orphan families. Nevertheless, the three-fold increase
in rare EIF4G1 coding variants in PD compared to control
subjects warrants further study. Common polymorphic
variability in the EIF4G1 locus was not associated with
PD in case-control samples.
These data suggest that eIF4G1 p.Ala502Val and
p.Arg1205His substitutions affect scaffold function
and consequently impair the ability of cells to rapidly
and dynamically respond to stress, presumably through
changes in the translation of existing mRNAs essential to
cell survival.9,10 Perturbations in mTOR/4E-BP signaling
and eIF4G1-mediated changes in mRNA translation will
be important to elucidate in neurons in vivo. The pathway
highlighted might represent a central theme in PD for
which targeted interventions already have therapeutic
potential.25Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG/.The AmericanAcknowledgments
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